Tsikouras Panagiotis, Christoforidou Anna, Bothou Anastasia, Deuteraiou Dorelia, Anthoulaki Xanthoula, Chalkidou Anna, Zervoudis Stefanos, Galazios Georgios
Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupoli, Greece.
Department of Haematology, Democritus University of Thrace, Alexandroupoli, Greece.
J Med Case Rep. 2018 Jun 16;12(1):169. doi: 10.1186/s13256-018-1711-2.
The risk of thromboembolic events during pregnancy in patients with antithrombin deficiency is increased. Preventing thromboembolic events during pregnancy in the case of antithrombin deficiency is still a matter of concern.
We present a case of a 19-year-old primigravida Greek Pomak woman, who was diagnosed as having congenital antithrombin deficiency. She had a history of recurrent miscarriages and a family history of thrombosis. She was managed with adjusted doses of low molecular weight heparin throughout her pregnancy, with regular anti-Xa and antithrombin level monitoring. Prior to delivery and for 4 days after delivery she received human antithrombin III concentrate. She delivered a small for gestational age baby with no other complications. She required an increased dose of heparin due to heparin resistance.
Antithrombin deficiency is associated with an increased risk of venous thromboembolic events with a 50% risk of thromboembolic events before the 50th year of life. It is a rare condition, so data concerning the optimal management during pregnancy are limited. The selection of patients who should receive low molecular weight heparin prophylaxis as well as dose intensity and monitoring are discussed. In our patient a conventional low molecular weight heparin dose proved to be inadequate at least at the laboratory level.
抗凝血酶缺乏患者在孕期发生血栓栓塞事件的风险增加。对于抗凝血酶缺乏患者,孕期预防血栓栓塞事件仍是一个令人关注的问题。
我们报告一例19岁初孕的希腊波马克族女性病例,该患者被诊断为先天性抗凝血酶缺乏。她有反复流产史及血栓家族史。整个孕期她接受调整剂量的低分子量肝素治疗,并定期监测抗Xa和抗凝血酶水平。分娩前及分娩后4天,她接受了人抗凝血酶III浓缩物治疗。她分娩了一个小于胎龄儿,无其他并发症。由于肝素抵抗,她需要增加肝素剂量。
抗凝血酶缺乏与静脉血栓栓塞事件风险增加相关,在50岁前发生血栓栓塞事件的风险为50%。这是一种罕见疾病,因此关于孕期最佳管理的数据有限。本文讨论了应接受低分子量肝素预防的患者选择、剂量强度及监测。在我们的患者中,至少在实验室水平上,常规低分子量肝素剂量被证明是不足的。